Superficial basal cell carcinoma on face treated with 5% imiquimod cream

Indian Journal of Dermatology, Venereology and Leprology

Volumn 72, Issue 5, 2006, Pages 373-375

  Malhotra, Amit Kumar ^a   Bansal, Arika ^a   Mridha, Asit R ^a   Khaitan, Binod K ^a   Verma, Kaushal K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Basal cell carcinoma; Imiquimod; Treatment

Indexed keywords

IMIQUIMOD;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; BASAL CELL CARCINOMA; CASE REPORT; CLINICAL FEATURE; CREAM; HUMAN; HYPERPIGMENTATION; MALE; SKIN EXAMINATION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 33750038557     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.27757     Document Type: Article

References (10)

1. Salasche S. Imiquimod 5% cream: A new treatment option for basal cell carcinoma. Int J Dermatol 2002;41:16-20.
2. Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999;41:1002-7.
3. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002;147:1227-36.
4. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002;47:390-8.
5. Tyring S, Conant M, Marini M, van der Meijden W, Washenik K. Imiquimod; An international update on therapeutic uses in dermatology. Int J Dermatol 2002;41:810-6.
6. Navi D, Huntley A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J 2004;10:4.
7. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphea. Br J Dermatol 2005;153:815-20.
8. Berman B, Poochareon VN, Villa AM. Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Therapy Lett 2002;7:1-6.
9. Jo JH, Chin HW, Kim MB, Oh CK, Jang HS, Kwon KS. A case of eccrine poroma treated with 5% imiquimod cream. J Dermatol 2005;32:691-3.
10. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139:1325-32.